Source: Archives of Ophthalmology
The 2-year outcomes of the BOLT study, a prospective RCT evaluating intravitreal bevacizumab* and modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT) in patients with persistent clinically significant macular oedema (CSMO) have been published.
The study involved 80 patients with center-involving CSMO and visual acuity of 20/40 to 20/320 who were randomised to receive either bevacizumab or MLT. The primary outcome was the difference in ETDRS best-corrected visual acuity (BCVA) between arms. Secondary outcomes were mean change in BCVA, proportion (Read more...)